ORION CORPORATION STOCK EXCHANGE RELEASE 20 March 2012 at 5.00 pm EET Orion Corporation: Organising meeting of the Board of Directors In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Jukka Ylppö as Vice Chairman. The compositions of the Board committees were decided to be as follows: Remuneration Committee: Hannu Syrjänen, Chairman Timo Maasilta Heikki Westerlund Audit Committee: Heikki Westerlund, Chairman Eero Karvonen Timo Maasilta Jukka Ylppö R&D Committee: Sirpa Jalkanen, Chairman Eero Karvonen Timo Maasilta Hannu Syrjänen Heikki Westerlund Jukka Ylppö The members to the Nomination Committee will be elected later. The Board of Directors has assessed the independence of its members and concluded that all the members are independent of the company and its significant shareholders. Orion Corporation Timo Lappalainen Olli Huotari President and CEO SVP, Corporate Functions Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler(®) pulmonary drugs. Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki. [HUG#1595840]